ARXX Therapeutics ApS: Financial statements 2025
CVR: 40868151
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
ARXX Therapeutics ApS (CVR 40868151) has filed annual accounts for 2025. In 2025, the company reported revenue of DKK 3,743,522 and a net result of DKK 706,595 compared with DKK 116,729 the year before. That is an increase of 43.5% compared with the year before. The profit margin was 18.9%. Equity in the 2025 report amounted to DKK 1,688,804. The solvency ratio was 87.6%.
- Revenue
- DKK 3,743,522
- Gross Profit
- DKK 2,787,890
- Profit/Loss
- DKK 706,595
- Equity
- DKK 1,688,804
- Total Assets
- DKK 1,926,867
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | 3.7M | 2.8M | 707K | 1.7M | - |
| 2024 | 2.6M | 2.3M | 117K | 982K | - |
| 2023 | 2.8M | 1.9M | 270K | 865K | - |
| 2022 | 5.8M | 2.2M | 507K | 596K | - |
| 2021 | 2.4M | 1.7M | 77K | 177K | - |
Official annual report
How creditworthy is ARXX Therapeutics ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
As of August 14, 2025, Farzad Abdi-Dezfuli has left the board of directors of ARXX Therapeutics ApS.
As of August 14, 2025, Jonas Hallén has left the board of directors of ARXX Therapeutics ApS.
As of August 14, 2025, Susanne Stuffers has left the board of directors of ARXX Therapeutics ApS.
As of August 14, 2025, Jonas Hallén is registered as director of ARXX Therapeutics ApS.
As of August 14, 2025, Berte Aagot Hedding Poulsson is registered as director of ARXX Therapeutics ApS.
As of August 14, 2025, Susanne Stuffers has stepped down as director of ARXX Therapeutics ApS.
ARXX Therapeutics ApS has published its annual report for 2024. Revenue came to DKK 2,608,206, and the net result was DKK 116,729.
About ARXX Therapeutics ApS
ARXX Therapeutics ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2019. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Berte Aagot Hedding Poulsson and Jonas Hallén. The company is owned by ARXX THERAPEUTICS AS. The company has 2 employees (2026). In 2025, the company reported revenue of DKK 3,743,522 and a net result of DKK 706,595 compared with DKK 116,729 the year before. Equity in the 2025 report amounted to DKK 1,688,804.